Cargando…

Hydralazine-Induced Lupus Syndrome Manifesting as Large Pericardial Effusion

Hydralazine-induced lupus syndrome (HILS) is a rare clinical entity with variable manifestations. Pericardial involvement is an uncommon but serious manifestation of the condition. In this report, we present a case of large symptomatic pericardial effusion secondary to HILS. We highlight the importa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Nathaniel R, Chauhan, Siddharth, Aisenberg, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500742/
https://www.ncbi.nlm.nih.gov/pubmed/32963908
http://dx.doi.org/10.7759/cureus.9867
_version_ 1783583916211306496
author Wilson, Nathaniel R
Chauhan, Siddharth
Aisenberg, Gabriel
author_facet Wilson, Nathaniel R
Chauhan, Siddharth
Aisenberg, Gabriel
author_sort Wilson, Nathaniel R
collection PubMed
description Hydralazine-induced lupus syndrome (HILS) is a rare clinical entity with variable manifestations. Pericardial involvement is an uncommon but serious manifestation of the condition. In this report, we present a case of large symptomatic pericardial effusion secondary to HILS. We highlight the important considerations in the evaluation and management of this rare syndrome. HILS should be considered in the differential diagnosis for cardiac tamponade of otherwise unclear etiology in patients taking 100 mg daily or more of hydralazine for longer than three months. A temporal association between the offending drug and presenting symptoms, resolution of symptoms upon discontinuation, and a positive anti-histone antibody test can all support the diagnosis of this syndrome.
format Online
Article
Text
id pubmed-7500742
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-75007422020-09-21 Hydralazine-Induced Lupus Syndrome Manifesting as Large Pericardial Effusion Wilson, Nathaniel R Chauhan, Siddharth Aisenberg, Gabriel Cureus Cardiology Hydralazine-induced lupus syndrome (HILS) is a rare clinical entity with variable manifestations. Pericardial involvement is an uncommon but serious manifestation of the condition. In this report, we present a case of large symptomatic pericardial effusion secondary to HILS. We highlight the important considerations in the evaluation and management of this rare syndrome. HILS should be considered in the differential diagnosis for cardiac tamponade of otherwise unclear etiology in patients taking 100 mg daily or more of hydralazine for longer than three months. A temporal association between the offending drug and presenting symptoms, resolution of symptoms upon discontinuation, and a positive anti-histone antibody test can all support the diagnosis of this syndrome. Cureus 2020-08-19 /pmc/articles/PMC7500742/ /pubmed/32963908 http://dx.doi.org/10.7759/cureus.9867 Text en Copyright © 2020, Wilson et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Wilson, Nathaniel R
Chauhan, Siddharth
Aisenberg, Gabriel
Hydralazine-Induced Lupus Syndrome Manifesting as Large Pericardial Effusion
title Hydralazine-Induced Lupus Syndrome Manifesting as Large Pericardial Effusion
title_full Hydralazine-Induced Lupus Syndrome Manifesting as Large Pericardial Effusion
title_fullStr Hydralazine-Induced Lupus Syndrome Manifesting as Large Pericardial Effusion
title_full_unstemmed Hydralazine-Induced Lupus Syndrome Manifesting as Large Pericardial Effusion
title_short Hydralazine-Induced Lupus Syndrome Manifesting as Large Pericardial Effusion
title_sort hydralazine-induced lupus syndrome manifesting as large pericardial effusion
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500742/
https://www.ncbi.nlm.nih.gov/pubmed/32963908
http://dx.doi.org/10.7759/cureus.9867
work_keys_str_mv AT wilsonnathanielr hydralazineinducedlupussyndromemanifestingaslargepericardialeffusion
AT chauhansiddharth hydralazineinducedlupussyndromemanifestingaslargepericardialeffusion
AT aisenberggabriel hydralazineinducedlupussyndromemanifestingaslargepericardialeffusion